P
PROK
vs
S&P 500
S&P 500
Over the past 12 months, PROK has significantly outperformed S&P 500, delivering a return of +42% compared to the S&P 500's +19% growth.
Stocks Performance
PROK vs S&P 500
Performance Gap
PROK vs S&P 500
Performance By Year
PROK vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ProKidney Corp
Glance View
ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.